Itabuna

Researchers are evaluating the effects of therapeutic-dose heparin compared to usual care pharmacological thromboprophylaxis in patients hospitalized with community-acquired pneumonia CAP. This international, open-label, randomized controlled trial aims to understand if higher doses of heparin can improve outcomes by addressing inflammatory and thrombotic processes that contribute to respiratory, cardiac, and organ complications in CAP. The study builds on findings from COVID-19 patients, where therapeutic-dose heparin showed benefits in non-critically ill patients. Participants are randomly assigned to one of two groups. One group receives a daily therapeutic dose of low molecular-weight heparin LMWH or unfractionated heparin UFH for up to 14 days or until hospital discharge. The other group receives usual care with thromboprophylactic dose anticoagulation following local protocols, with doses not exceeding half the therapeutic level. The investigational arm prefers LMWH but may use UFH, especially in cases of renal compromise, with dosing tailored to patient weight and local standards. During the study, participants will be monitored for survival over 30 days as the primary outcome. Secondary outcomes include bleeding events, heparin-induced thrombocytopenia HIT, thrombotic events, invasive mechanical ventilation, mortality at multiple time points, hospital-free days, and health-related quality of life. The study involves hospital assessments, close monitoring of safety and clinical status, and tracking of various health measures up to 180 days, ensuring comprehensive evaluation of the treatments under study.

This research aims to map breast and prostate cancer in patients treated through the Brazilian Unified Health System by performing complete sequencing of tumor somatic and germline exomes. It focuses on understanding molecular variants in tumors, which can affect treatment response and disease prognosis. The project also seeks to identify hereditary genetic syndromes and collect data on the populations ancestry for the Brazilian Ministry of Healths National Precision Genomics and Health Program, Genomas Brasil. The study includes two groups 745 patients with HER2-positive and triple-negative breast cancer who underwent neoadjuvant therapy followed by surgery, and 137 patients with metastatic prostate cancer. Sequencing involves somatic and germline whole exome analysis for prostate and HER2-positive breast cancer, and somatic whole exome with germline whole genome sequencing for triple-negative breast cancer. Participants will provide tumor tissue and blood samples for genomic analysis. Researchers will characterize complete somatic and germline exomesgenomes within 12 months, identify genetic variants related to tumor prognosis and treatment response, and count patients with mutations in cancer-predisposing genes. The study runs until 2026 and data will support precision oncology efforts in Brazil.